Search
for

    Sort by

    Research

    420-450 / 1000+ results

      research Finasteride

      August 2009 in “Reactions Weekly”

      research Finasteride

      February 2009 in “Reactions Weekly”

      research Finasteride

      October 2008 in “Reactions Weekly”

      research Finasteride

      October 2008 in “Reactions Weekly”

      research Finasteride

      February 2008 in “Reactions Weekly”

      research Finasteride

      November 2007 in “Reactions Weekly”

      research Finasteride

      January 2004 in “Reactions Weekly”

      research Finasteride

      March 2003 in “Reactions Weekly”

      research Finasteride

      October 2002 in “Reactions Weekly”

      research Finasteride

      September 2002 in “Reactions Weekly”

      research Finasteride

      February 2023 in “Reactions Weekly”

      research Finasteride

      January 2023 in “Reactions Weekly”

      research Finasteride

      May 2022 in “Reactions Weekly”

      research Finasteride

      December 2021 in “Reactions Weekly”

      research Finasteride

      January 2014 in “Reactions Weekly”

      research Finasteride

      August 2011 in “Reactions Weekly”

      research Polymorphism

      September 2008
      This chapter discusses phase transitions in various pharmaceutical examples and does not present any new research findings.

      research Finasteride

      April 2015 in “Reactions Weekly”

      research Finasteride

      May 2013 in “Reactions Weekly”

      research Finasteride

      December 2012 in “Reactions Weekly”

      research Finasteride

      January 2009 in “Reactions Weekly”
      Steroid 5α-Reductase Inhibitors

      research Steroid 5α-Reductase Inhibitors

      42 citations , May 2003 in “Mini-reviews in Medicinal Chemistry”
      This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.
      Palladium Nanoparticles on a Pyridinium Supported Ionic Liquid Phase: A Recyclable and Low-Leaching Palladium Catalyst for Aminocarbonylation Reactions

      research Palladium nanoparticles on a pyridinium supported ionic liquid phase: a recyclable and low-leaching palladium catalyst for aminocarbonylation reactions

      15 citations , January 2020 in “RSC advances”
      In this study, researchers developed a new Supported Ionic Liquid Phase palladium catalyst that showed effectiveness in aminocarbonylation reactions for synthesizing pharmaceutical compounds like CX-546 and a precursor of Finasteride, though results were sensitive to substrate variations and prompted palladium leaching concerns.

      research SUN-364 Panhypopituitarism Induced Ventricular Tachycardia: Hormonal Relationship All Should Keep in Mind

      October 2025 in “Journal of the Endocrine Society”
      This case report describes a 36-year-old female patient with panhypopituitarism, experiencing severe adrenal insufficiency and thyroid hormone deficiency, which led to electrolyte imbalance, QT interval prolongation, and ventricular tachycardia; treatment stabilized her condition, underscoring the importance of hormonal evaluation in arrhythmia assessment.
      Sudden Akathisia After a Ziprasidone Dose Reduction

      research Sudden Akathisia After a Ziprasidone Dose Reduction

      16 citations , March 2006 in “˜The œAmerican journal of psychiatry”
      This report describes five cases where sudden akathisia occurred in female patients with bipolar disorder after a ziprasidone dose reduction, emphasizing potential unexpected side effects of second-generation antipsychotics.
      Tamsulosin and Solifenacin: A Dynamic Duo in BPH Management

      research Tamsulosin and Solifenacin : A Dynamic Duo in BPH Management

      July 2025 in “International Journal of Health and Medicine”
      In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.